Phase II Study of Amrubicin Combined with Carboplatin for Thymic Carcinoma and Invasive Thymoma: North Japan Lung Cancer Group Study 0803Akira Inoue, Toshihiro Nukiwa, Shunichi Sugawara et al.|Journal of Thoracic Oncology|2014Cited by 46
Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203Yoko Tsukita, Masakazu Ichinose, Taku Nakagawa et al.|Lung Cancer|2019Cited by 27
TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancerIsamu Okamoto, Aaron Lisberg, Shoichi Kuyama et al.|Future Oncology|2024Cited by 20
A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027Yuji Minegishi, Akihiko Gemma, Ou Yamaguchi et al.|BMC Cancer|2021Cited by 18
Phase II study of amrubicin (AMR) and carboplatin (CBDCA) for invasive thymoma (IT) and thymic carcinoma (TC): NJLCG0803.Yosuke Kawashima, Toshihiro Nukiwa, Akira Inoue et al.|Journal of Clinical Oncology|2013Cited by 6